Մալթա - անգլերեն - Medicines Authority

accord healthcare limited - nevirapine, anhydrous - prolonged-release tablet - nevirapine, anhydrous 400 mg - antivirals for systemic use

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - mirabegron, quantity: 50 mg - tablet, modified release - excipient ingredients: macrogol 2000000; macrogol 8000; purified water; butylated hydroxytoluene; hyprolose; magnesium stearate; hypromellose; iron oxide yellow - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - mirabegron, quantity: 25 mg - tablet, modified release - excipient ingredients: butylated hydroxytoluene; magnesium stearate; hyprolose; purified water; macrogol 2000000; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

johnson & johnson pte. ltd. - (drug layer) hydromorphone hcl - tablet, extended release - 8.72mg - (drug layer) hydromorphone hcl 8.72mg

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

astellas pharma singapore pte. ltd. - mirabegron - tablet, film coated, extended release - 25 mg - mirabegron 25 mg

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

astellas pharma singapore pte. ltd. - mirabegron - tablet, film coated, extended release - 50 mg - mirabegron 50 mg

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nevirapine, quantity: 400 mg - tablet, modified release - excipient ingredients: lactose monohydrate; hypromellose; iron oxide yellow; magnesium stearate - viramune (nevirapine) oral suspension in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of 2 months. viramune xr (nevirapine) extended-release tablets in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of three years. extended-release tablets are not suitable for the 14 day lead-in period for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used. resistant virus emerges rapidly when viramune is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, viramune should always be administered in combination with at least two additional antiretroviral agents.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; povidone; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; povidone; magnesium stearate; colloidal anhydrous silica - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; copovidone; magnesium stearate; hypromellose; microcrystalline cellulose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin